Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
… EGFR mutations who received first-line gefitinib, erlotinib or afatinib treatment, followed by
osimertinib upon disease progression with acquired T790M mutation, … with first-line EGFR-TKI (…
osimertinib upon disease progression with acquired T790M mutation, … with first-line EGFR-TKI (…
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
… largely concentrated on common EGFR mutations, reflecting … analysis of compound EGFR
mutations (two uncommon mutations) … to different EGFR TKIs (erlotinib, gefitinib, afatinib, and …
mutations (two uncommon mutations) … to different EGFR TKIs (erlotinib, gefitinib, afatinib, and …
[HTML][HTML] … different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
… with gefitinib or erlotinib after adjusting for both EGFR mutation … among the three most
commonly available TKIs. Therefore, … most commonly available first- or second-generation EGFR …
commonly available TKIs. Therefore, … most commonly available first- or second-generation EGFR …
… of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and …
J Tan, C Hu, P Deng, R Wan, L Cao, M Li… - Frontiers in …, 2021 - frontiersin.org
… , afatinib was associated with significantly favorable ORRs and mPFS than gefitinib/erlotinib/…
of multivariate analysis showed that concomitant common EGFR mutation is a predictor for …
of multivariate analysis showed that concomitant common EGFR mutation is a predictor for …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
… Both gefitinib and erlotinib have been … with gefitinib in 319 treatment-naive patients (160
randomized to afatinib and 159 to gefitinib) with NSCLC harboring common EGFR mutations (…
randomized to afatinib and 159 to gefitinib) with NSCLC harboring common EGFR mutations (…
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
… gefitinib and erlotinib, and longer OS than erlotinib. In cases of compound common EGFR
mutations, … in terms of response (RR: gefitinib 83%, erlotinib 73.7%, afatinib 88.2%) and PFS (…
mutations, … in terms of response (RR: gefitinib 83%, erlotinib 73.7%, afatinib 88.2%) and PFS (…
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
R Garcia-Campelo, O Arrieta, B Massuti… - Lung Cancer, 2020 - Elsevier
… detect the most common EGFR sensitizing mutations, as well … with shorter PFS in erlotinib
treated EGFR mutant patients [15… receiving gefitinib alone or those receiving gefitinib plus …
treated EGFR mutant patients [15… receiving gefitinib alone or those receiving gefitinib plus …
… Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - Springer
… compared with gefitinib in patients with EGFR mutation after a … with osimertinib versus
gefitinib/erlotinib was consistent … (including less common EGFR-activating mutations), with or …
gefitinib/erlotinib was consistent … (including less common EGFR-activating mutations), with or …
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
RF Dong, ML Zhu, MM Liu, YT Xu, LL Yuan… - Pharmacological …, 2021 - Elsevier
… of EGFR T790M clones late in the process of gefitinib … The EGFR C797S mutation is the most
common mutation conferring … achieved a partial response to the treatment with erlotinib and …
common mutation conferring … achieved a partial response to the treatment with erlotinib and …
A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma
M Sharma, DA Basu, S Nathany… - Cancer Research …, 2022 - journals.lww.com
… [ 92 ] FLAURA was a double-blind trial that evaluated the efficacy of osimertinib versus
erlotinib or gefitinib in the first-line setting for EGFR-mutant metastatic NSCLC. Osimertinib …
erlotinib or gefitinib in the first-line setting for EGFR-mutant metastatic NSCLC. Osimertinib …
相关搜索
- first line setting common egfr mutation
- treatment strategies common egfr mutations
- pathogenesis and treatment common egfr mutations
- uncommon egfr mutations
- egfr mutations clinical outcomes
- egfr mutations non-small cell lung carcinoma
- gefitinib erlotinib and afatinib
- patients with egfr mutation
- sensitive egfr mutations gefitinib and chemotherapy
- sensitive egfr mutation afatinib in patients
- egfr mutation 1st generation
- survival benefits common egfr mutation
- lung carcinoma common egfr mutations
- cell lung cancer common egfr mutations
- narrative review common egfr mutations
- egfr mutations non-small cell lung cancer